Doxycycline is indicated for a variety of infections when caused by susceptible strains of microorganisms, including respiratory tract and urinary tract infections, skin and skin structure infections, and severe acne as adjunctive therapy.
According to sources quoted by the company, annual market sales for Adoxa were $57.2 million.
“Ranbaxy is pleased to receive this most recent approval from the US FDA. Doxycycline will add to our ever-expanding product portfolio of affordable generic alternatives that will have a positive effect on the economics of healthcare,” said Jim Meehan, VP of sales and marketing for Ranbaxy.
Ranbaxy Pharmaceuticals based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories, India’s largest pharmaceutical company.